Browsing Tag
pancreatic ductal adenocarcinoma
3 posts
How elraglusib’s long-term Phase 2 survival data positions Actuate Therapeutics in a difficult pancreatic cancer market
Find out how elraglusib’s long-term Phase 2 survival data is positioning Actuate Therapeutics in the challenging metastatic pancreatic cancer market.
Incyte’s dual-target antibody and KRAS G12D drug show early promise in hard-to-treat colorectal and pancreatic cancers
Find out how Incyte’s Phase 1 cancer data could transform treatment for colorectal and pancreatic patients—read what’s driving investor optimism today!
Biomea Fusion to take BMF-219 into clinical trials for KRAS solid tumors
Biomea Fusion is all set to take BMF-219 into clinical trials in patients having unresectable, locally advanced, or…